dual PI3K-alpha/PARP-1 inhibitors (China Pharmaceutical University)

N/A

Report date: 2025/03/18 18:12:11
NME

Base Information

Drug Namedual PI3K-alpha/PARP-1 inhibitors (China Pharmaceutical University)
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPhosphatidylinositol 3 kinase alpha inhibitorsPoly (ADP-Ribose) polymerase 1 inhibitors
TargetsPoly (ADP-Ribose) polymerase 1Phosphatidylinositol 3 kinase alpha
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesChina Pharmaceutical University
China Registration ClassN/A

Develop Information

Active CompaniesChina Pharmaceutical University
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A